What's in Hamilton Health Sciences Corporation's pipeline?

Hamilton Health Sciences Corporation has 28 drugs in our index: 11 marketed, 0 filed, 11 in Phase 3, 4 in Phase 2, 2 in Phase 1.

Which companies overlap with Hamilton Health Sciences Corporation's portfolio?

Top competitors by shared drug class: Seoul National University Hospital, Benaroya Research Institute, Henry Ford Health System, Massachusetts General Hospital, Organon and Co.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hamilton-health-sciences-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Hamilton Health Sciences Corporation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hamilton Health Sciences Corporation pipeline: 11 marketed, 0 filed, 11 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 11 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
PEG 3350	PEG 3350	marketed	Osmotic laxative		Gastroenterology
Active ASA	Active ASA	marketed	Nonsteroidal Anti-Inflammatory Drug (NSAID)	Cyclooxygenase (COX) enzymes	Pain
budesonide 400 mcg	budesonide 400 mcg	marketed
Topical Antibiotic	Topical Antibiotic	marketed
Active Clonidine	Active Clonidine	marketed
optimizing therapeutic treatments	optimizing therapeutic treatments	marketed
Depo-Medrol	Depo-Medrol	marketed	Corticosteroid (glucocorticoid)	Glucocorticoid receptor	Immunology / Rheumatology / General anti-inflammatory
Olanzapine & Quetiapine	Olanzapine & Quetiapine	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor	Psychiatry
Vitamins: Folic acid, B6, B12	Vitamins: Folic acid, B6, B12	marketed	Vitamin supplement / B-complex		Nutritional supplementation / Preventive health
Warfarin vs ASA	Warfarin vs ASA	marketed	Anticoagulant (warfarin) and antiplatelet agent (aspirin)	Vitamin K-dependent clotting factors (warfarin); cyclooxygenase (aspirin)	Cardiovascular
CBD+THC	CBD+THC	marketed			Neuroscience
Desmopressin Injectable Solution	Desmopressin Injectable Solution	phase 3	Vasopressin analog	V2 receptor (vasopressin receptor 2)	Endocrinology

Therapeutic area mix

Cardiovascular / Surgery · 2
Critical Care / Intensive Care Medicine · 1
Endocrinology · 1
Gastroenterology · 1
Immunology / Rheumatology / General anti-inflammatory · 1
Infection Prevention / Surgery · 1
Infectious Diseases · 1
Neuroscience · 1
Nutritional supplementation / Preventive health · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Seoul National University Hospital · 3 shared drug classes
Benaroya Research Institute · 2 shared drug classes
Henry Ford Health System · 2 shared drug classes
Massachusetts General Hospital · 2 shared drug classes
Organon and Co · 2 shared drug classes
University of Rochester · 2 shared drug classes
Alexza Pharmaceuticals, Inc. · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hamilton Health Sciences Corporation:

Cite this brief

Drug Landscape (2026). Hamilton Health Sciences Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hamilton-health-sciences-corporation. Accessed 2026-05-17.